Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | ARG2 | P78540 | 3/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563056 | 1.00 | CYP1A2 (0.52) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL497762 | 0.88 | GRM2 (0.46) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL1301353 | 0.83 | CYP1A2 (0.48) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL3100826 | 0.82 | GRM2 (0.42) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL3100821 | 0.82 | GRM2 (0.42) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL6518490 | 0.82 | MEN1 (0.38) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL6518493 | 0.82 | MEN1 (0.38) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL20221433 | 0.80 | MEN1 (0.36) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL17143589 | 0.80 | ODC1 (0.48) | CYP1A2MEN1KMT2AALDH1A1THRB | |
| SCHEMBL16222675 | 0.80 | GRM2 (0.41) | CYP1A2MEN1KMT2AALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4172180-A1 | USES, METHODS AND PRODUCTS RELATING TO OLIGOMERIC LIPOPOLYSACCHARIDE BINDING PROTEINS | Universitetet I Oslo (NO) | 2023-05-03 | — | — | EP | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2222165-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-2038266-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | CYP1A2 4431/4885MEN1 567/4885KMT2A 3419/4885 |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CYP1A2 234/4885MEN1 1534/4885KMT2A 1378/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | CYP1A2 238/4885MEN1 1218/4885KMT2A 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.